⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
globenewswire.com
KYMR
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
KYMR
GILD
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
globenewswire.com
KYMR
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
globenewswire.com
KYMR
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
globenewswire.com
KYMR
GILD